Skip to content
Malta's world news feed Local perspective with global outlook
CDE.NEWS The Dispatch
Malta Insights

“Europe’s Challenge Is Turning Innovation Into Patient Access.”

– Dr Armando Magrelli, Head of the International Relations Office at the Italian Medicines Agency (AIFA).

A medicine’s approval at European level does not necessarily mean that patients across the EU can access it at the same time. “One of Europe’s greatest challenges remains the gap between the authorisation of innovative medicines at European level and their effective availability to patients across Member States,” says Dr Armando Magrelli, Head of the International Relations Office at the Italian Medicines Agency (AIFA).

Dr Magrelli, who is also Italy’s alternate representative on the European Medicines Agency (EMA) Management Board will be addressing the forthcoming HekaTech Health 2026 Conference on the 26th of November where he will be discussing Europe’s medicines access challenge, Italy’s experience and the importance of translating scientific innovation into patient benefits.

“The gap between regulatory authorisation and actual patient access remains one of Europe’s most significant healthcare challenges because while medicines benefit from a common European regulatory framework, their availability depends on national decisions concerning pricing, reimbursement and healthcare delivery,” he explains.

Dr Magrelli acknowledged that for smaller Member States such as Malta, this raises important questions about how patients can benefit from innovation in a timely and equitable way especially given that “one of Europe’s greatest challenges is the gap between the authorisation of innovative medicines at European level and their effective availability to patients across Member States.”

He notes AIFA’s central role in ensuring access to medicines that are safe, effective and of appropriate therapeutic value, while safeguarding the sustainability of Italy’s National Health Service. Its responsibilities include evaluating therapeutic value, negotiating prices and reimbursement conditions, and monitoring pharmaceutical expenditure.

“Italy is recognised for its structured approach to facilitating access to innovative medicines, combining dedicated funding, scientific assessment and monitoring mechanisms. Our objective is to ensure that therapeutic innovation translates into meaningful benefits for patients, within a healthcare system based on universal coverage and solidarity.”

“One of Italy’s most significant achievements has been the development of a structured framework to facilitate access to innovative medicines through the National Health Service. This dedicated funding is complemented by AIFA’s monitoring registries and managed entry agreements, which help address uncertainties surrounding new treatments and inform reimbursement decisions.”

“The value of the Italian experience lies not in any single instrument, but in combining scientific assessment, financial mechanisms and monitoring tools within a universal healthcare system. Nevertheless, ensuring timely and equitable access across all Italian regions remains an important challenge.”

Dr Magrelli agrees that patient access and financial sustainability should not be viewed as competing objectives however, he believes that a healthcare system can provide equitable access to innovation only if it remains financially sustainable.

He explains how Italy combines health technology assessment (HTA), price and reimbursement negotiations, medicines utilisation monitoring and managed entry agreements to evaluate therapeutic benefits while managing clinical and financial uncertainties. Generating real-world evidence and monitoring medicines throughout their lifecycle are also important.

“The objective is not simply to contain expenditure, but to maximise the health benefits delivered by the resources available.”

Dr Magrelli stresses the distinction between European marketing authorisation and national decisions on pricing, reimbursement and therapeutic innovativeness.

“A European marketing authorisation establishes that a medicine meets the applicable requirements for quality, safety and efficacy. However, reimbursement decisions must also consider its therapeutic value in relation to existing alternatives and the implications for the healthcare system.”

“In Italy, therapeutic innovativeness is assessed against three dimensions: unmet therapeutic need, added therapeutic value and the quality of supporting scientific evidence. This approach is therefore not based simply on prioritising specific disease areas, but on assessing the therapeutic contribution of each medicine in its relevant clinical context.”

Dr Magrelli believes greater European cooperation, particularly through the implementation of the EU Health Technology Assessment Regulation, is an opportunity to improve the consistency and efficiency of clinical assessments.

“Achieving more equitable access will also require stronger coordination between regulatory authorities, HTA bodies, healthcare payers and other stakeholders, while respecting the different responsibilities of national healthcare systems. For Malta, like other member states, the challenge is to translate European cooperation and scientific progress into practical improvements in patient access.

Ahead of his participation at HekaTech Health 2026, Dr Magrelli’s message is that access to innovative medicines cannot be achieved through regulatory approval alone but through an integrated approach in which scientific evaluation, reimbursement policies, sustainable financing and healthcare delivery work together towards a common objective: improving patient outcomes.

“Innovation only fulfils its promise when it reaches the patients who need it. Our collective responsibility is to make that access timely, equitable and sustainable.”

The full day conference Hekatech.Health will be held on Thursday 26th November at The Olympia, Doubletree in Qawra. For registrations and more information on the full programme of speakers, visit www.hekatech.health

More from Malta Insights

More →